Nephros (NASDAQ:NEPH) Trading Down 0.3% – What’s Next?

Shares of Nephros Inc. (NASDAQ:NEPH) fell 0.3% during trading on Tuesday . The company traded as low as $3.51 and last traded at $3.57. 3,966 shares traded hands during mid-day trading, a decline of 67% from the average session volume of 12,140 shares. The stock had previously closed at $3.58.

Analyst Ratings Changes

Separately, Weiss Ratings raised shares of Nephros from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, June 18th. One analyst has rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $6.00.

Nephros Stock Down 0.3%

The company has a market cap of $38.77 million, a PE ratio of 51.01 and a beta of 1.51. The stock has a 50-day moving average of $3.34 and a 200-day moving average of $3.77.

Nephros (NASDAQ:NEPH) last posted its earnings results on Thursday, May 7th. The company reported $0.01 EPS for the quarter, hitting the consensus estimate of $0.01. The business had revenue of $5.21 million during the quarter, compared to analysts’ expectations of $5.02 million. Nephros had a return on equity of 7.66% and a net margin of 4.06%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Dimensional Fund Advisors LP raised its stake in Nephros by 52.5% in the first quarter. Dimensional Fund Advisors LP now owns 20,745 shares of the company’s stock valued at $62,000 after purchasing an additional 7,144 shares in the last quarter. XTX Topco Ltd grew its stake in Nephros by 48.5% in the 4th quarter. XTX Topco Ltd now owns 21,617 shares of the company’s stock worth $105,000 after buying an additional 7,062 shares in the last quarter. Quadrature Capital Ltd bought a new position in shares of Nephros in the 4th quarter worth $112,000. Kestra Advisory Services LLC bought a new position in shares of Nephros in the 4th quarter worth $29,000. Finally, Marshall Wace LLP purchased a new stake in shares of Nephros during the 4th quarter valued at $107,000. Hedge funds and other institutional investors own 41.10% of the company’s stock.

About Nephros

Nephros, Inc is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems.